KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBT (2016 - 2025)

Charles River Laboratories International has reported EBT over the past 17 years, most recently at -$294.1 million for Q4 2025.

  • Quarterly results put EBT at -$294.1 million for Q4 2025, down 35.66% from a year ago — trailing twelve months through Dec 2025 was -$99.5 million (down 206.86% YoY), and the annual figure for FY2025 was -$99.5 million, down 206.86%.
  • EBT for Q4 2025 was -$294.1 million at Charles River Laboratories International, down from $87.2 million in the prior quarter.
  • Over the last five years, EBT for CRL hit a ceiling of $244.9 million in Q4 2022 and a floor of -$294.1 million in Q4 2025.
  • Median EBT over the past 5 years was $116.3 million (2023), compared with a mean of $83.9 million.
  • Biggest five-year swings in EBT: surged 67.18% in 2022 and later crashed 203.87% in 2024.
  • Charles River Laboratories International's EBT stood at $163.6 million in 2021, then surged by 49.67% to $244.9 million in 2022, then fell by 14.79% to $208.7 million in 2023, then crashed by 203.87% to -$216.8 million in 2024, then tumbled by 35.66% to -$294.1 million in 2025.
  • The last three reported values for EBT were -$294.1 million (Q4 2025), $87.2 million (Q3 2025), and $71.4 million (Q2 2025) per Business Quant data.